



00-2205 6 mL
Levamisole Solution (20x)
Lot No.

LEVAMISOLE SOLUTION

ENDOGENOUS ALKALINE PHOSPHATASE INHIBITOR

FORM:

Liquid. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM.

APPLICATION:

This solution will inhibit endogenous alkaline phosphatase activity in tissues or cells, except intestinal alkaline phosphatase. It also reduces the intensity of specific staining to some extent. Therefore, do not use routinely, if the tissue does not have endogenous alkaline phosphatase.

RECOMMENDED GUIDELINES FOR USE:

To inhibit endogenous alkaline phosphatase activity, add 1 drop (50 microliters) of this solution to 1 ml of ready-to-use alkaline phosphatase substrate solution before use.

STORAGE:

Store at 2-8°C.

Authorized Representative for IVDD 98/79/EC: Invitrogen Ltd.
Inchinnan Business Park
3 Fountain Drive
Paisley
PA4 9RF
UK

For In Vitro Diagnostic Use. CAUTION: Not for human or animal therapeutic use. Uses other than the labeled intended use may be a violation of local law

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288

E-mail: techsupport@invitrogen.com

PI002205

(Rev 10/09) DCC-09-1507

© 2007 Invitrogen Corporation. All right reserved. These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.



00-2205 6 mL
Levamisole Solution (20x)
Lot No.

LEVAMISOLE SOLUTION

ENDOGENOUS ALKALINE PHOSPHATASE INHIBITOR

FORM:

Liquid. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM.

APPLICATION:

This solution will inhibit endogenous alkaline phosphatase activity in tissues or cells, except intestinal alkaline phosphatase. It also reduces the intensity of specific staining to some extent. Therefore, do not use routinely, if the tissue does not have endogenous alkaline phosphatase.

RECOMMENDED GUIDELINES FOR USE:

To inhibit endogenous alkaline phosphatase activity, add 1 drop (50 microliters) of this solution to 1 ml of ready-to-use alkaline phosphatase substrate solution before use.

STORAGE:

Store at 2-8°C.

Authorized Representative for IVDD 98/79/EC: Invitrogen Ltd.
Inchinnan Business Park
3 Fountain Drive
Paisley
PA4 9RF
UK

For In Vitro Diagnostic Use. CAUTION: Not for human or animal therapeutic use. Uses other than the labeled intended use may be a violation of local law

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288

E-mail: techsupport@invitrogen.com

PI002205

(Rev 10/09) DCC-09-1507

© 2007 Invitrogen Corporation. All right reserved. These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.



00-2205 6 ml
Levamisol
Solución (20x)

LEVAMISOL SOLUCIÓN

INHIBIDOR DE LA FOSFATASA ALCALINA ENDÓGENA

FORMA:

Líquido. El levamisol en solución viene en forma de concentrado (20x). La concentración final de levamisol en la solución de sustrato será 1mM.

APLICACIÓN:

Esta solución inhibirá la actividad endógena de la fosfatasa alcalina en tejidos o células, con excepción de la fosfatasa alcalina intestinal. También reduce en parte la intensidad de la tinción específica. Por lo tanto no se debe usar de manera rutinaria si el tejido no tiene fosfatasa alcalina endógena.

RECOMENDACIONES DE USO:

Para inhibir la actividad endógena de la fosfatasa alcalina, agregar, antes de usar, 1 gota (50 microlitros) de esta solución a 1 ml de solución de sustrato de fosfatasa alcalina listo para usar.

ALMACENAMIENTO:

Almacenar a 2-8 °C.

Representante autorizado de IVDD 98/79/EC: Invitrogen Ltd.
Inchinnan Business Park
3 Fountain Drive
Paisley
PA4 9RF
UK

**SI TIENE ALGUNA PREGUNTA SOBRE ESTE PRODUCTO, DIRÍJASE A SU
DISTRIBUIDOR LOCAL.**

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288

E-mail: techsupport@invitrogen.com

PI002205

(Rev 10/09) DCC-09-1507

© 2007 Invitrogen Corporation. All right reserved. These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.



00-2205 6 ml
Solution de
lévamisole (20x)

SOLUTION DE LÉVAMISOLE

INHIBITEUR DE LA PHOSPHATASE ALCALINE ENDOGÈNE

FORME :

Liquide. La solution de lévamisole est fournie sous forme concentrée (20x). La concentration finale de lévamisole dans la solution de substrat sera de 1 mM.

APPLICATION :

Cette solution inhibera l'activité de la phosphatase alcaline endogène dans les tissus ou dans les cellules, à l'exception de la phosphatase alcaline intestinale. Elle réduit également l'intensité de toute coloration spécifique jusqu'à un certain point. Par conséquent, ne pas l'utiliser systématiquement si le tissu n'a pas de phosphatase alcaline endogène.

DIRECTIVES D'UTILISATION RECOMMANDÉES :

Pour inhiber l'activité de la phosphatase alcaline endogène, ajouter une goutte (50 microlitres) de cette solution à 1 ml de solution de substrat de phosphatase prête à l'emploi alcaline avant l'emploi.

STOCKAGE :

Conserver entre 2 et 8 °C.

Représentant Autorisé pour IVDD 98/79/EC: Invitrogen Ltd.
Inchinnan Business Park
3 Fountain Drive
Paisley
PA4 9RF
UK

**SI VOUS AVEZ DES QUESTIONS SUR CE PRODUIT CONTACTEZ
VOTRE DISTRIBUTEUR LOCAL**

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288

E-mail: techsupport@invitrogen.com

PI002205

(Rev 10/09) DCC-09-1507

© 2007 Invitrogen Corporation. All right reserved. These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.



00-2205 6 ml
Soluzione (20x)
Levamisole

SOLUZIONE LEVAMISOLE

INIBITORE DELLA FOSFATASI ALCALINA ENDOGENA

FORMA:

Liquido. La soluzione Levamisole è fornita in forma concentrata (20x). La concentrazione finale di Levamisole nella soluzione di substrato corrisponde a 1 mM.

APPLICAZIONE:

Questa soluzione inibisce la fosfatasi alcalina endogena nei tessuti o cellule, ad eccezione della fosfatasi alcalina intestinale. Essa, tuttavia, incide anche sulla colorazione specifica riducendone lievemente l'intensità. Astenersi pertanto dal farne un uso regolare se il tessuto non presenta alcuna fosfatasi alcalina endogena.

RACCOMANDAZIONI PER L'USO:

Per inibire l'attività della fosfatasi alcalina endogena aggiungere, prima dell'uso, 1 goccia (50 microlitri) di questa soluzione per ogni ml di soluzione di substrato di fosfatasi alcalina pronta per l'uso.

CONSERVAZIONE:

Conservare a 2-8 °C.

Rappresentante Autorizzato per IVDD 98/79/EC: Invitrogen Ltd.
Inchinnan Business Park
3 Fountain Drive
Paisley
PA4 9RF
UK

**PER DOMANDE INERENTI IL PRODOTTO SIETE PREGATI DI CONTATTARE IL
DISTRIBUTORE A VOI PIÙ VICINO.**

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288

E-mail: techsupport@invitrogen.com

PI002205

(Rev 10/09) DCC-09-1507

© 2007 Invitrogen Corporation. All right reserved. These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.



00-2205 6 ml
Levamisol-
Lösung (20x)

LEVAMISOL-LÖSUNG

ENDOGENER ALKALISCHER PHOSPHATASE-INHIBITOR

FORMULIERUNG:

Flüssigkeit. Levamisol-Lösung wird in konzentrierter Form geliefert (20x). Die endgültige Konzentration von Levamisol in der Substratlösung ist 1 mM.

ANWENDUNG:

Diese Lösung inhibiert die endogene alkalische Phosphataseaktivität in Geweben oder Zellen, mit Ausnahme von intestinaler alkalischer Phosphatase. Sie reduziert auch in bestimmten Ausmaß die Intensität der spezifischen Färbung. Deshalb sollte sie nicht routinemäßig verwendet werden, wenn das Gewebe keine endogene alkalische Phosphatase hat.

EMPFOHLENE RICHTLINIEN FÜR DEN GEBRAUCH:

Um die endogene alkalische Phosphataseaktivität zu inhibieren, vor dem Gebrauch 1 Tropfen (50 Mikroliter) dieser Lösung 1 ml der gebrauchsfertigen alkalischen Phosphatasesubstratlösung hinzugeben.

AUFBEWAHRUNG:

Bei 2-8°C aufbewahren.

Bevollmächtigter Repräsentant für IVDD 98/79/EC: Invitrogen Ltd.
Inchinnan Business Park
3 Fountain Drive
Paisley
PA4 9RF
UK

**SOLLTEN SIE IRGENDWELCHE FRAGEN ÜBER DIESES PRODUKTE HABEN,
MELDEN SIE SICH BITTE BEI IHREM ÖRTLICHEN VERTEILER.**

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288

E-mail: techsupport@invitrogen.com

PI002205

(Rev 10/09) DCC-09-1507

© 2007 Invitrogen Corporation. All right reserved. These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.